Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Company Research
Source: GlobeNewswire
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411 Watch the “What this Means” segment here PRINCETON, NJ, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced that Pankaj Mohan, PhD, Chief Executive Officer of Sonnet, and John Cini, PhD, Chief Scientific Officer of Sonnet, participated in a Virtual Investor “What this Means” segment released by Sonnet. As part of the segment, Drs. Mohan and Cini discussed the recent U.S. Patent titled, “Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same,” covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of
Show less
Read more
Impact Snapshot
Event Time:
SONN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SONN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SONN alerts
High impacting Sonnet BioTherapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SONN
News
- Peripheral Nerve Injuries Market to Show Remarkable Growth at a CAGR of 6.19% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug CandidatesGlobeNewswire
- Sonnet BioTherapeutics regains compliance with Nasdaq [Seeking Alpha]Seeking Alpha
- Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq [Yahoo! Finance]Yahoo! Finance
SONN
Sec Filings
- 11/8/24 - Form 8-K
- 11/7/24 - Form 424B4
- 11/7/24 - Form EFFECT
- SONN's page on the SEC website